Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention

Clinical Cardiology

Volumn 33, Issue 1, 2010, Pages

  Azar, Rabih R ^a   Badaoui, Georges ^a   Sarkis, Antoine ^a   Kassab, Roland ^a   Salaḿe, Elie ^a   Aboujaoudé, Simon ^a   Hamdan, Righab ^a   Barakett, Vanda ^a   Germanos, Mirna ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CREATINE KINASE MB; INTERLEUKIN 6; TIROFIBAN; TROPONIN I;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION;

ANGIOPLASTY, BALLOON, CORONARY; ANTIGENS, CD40; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CREATINE KINASE, MB FORM; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TYROSINE;

EID: 74949121130     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20424     Document Type: Article

References (19)

1. Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, et al.: Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol. 1997;80:1476-1478.
2. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, et al.: Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935-1942.
3. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, et al.: Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
4. Azar RR, Badaoui G, Sarkis A, Kassab R, Salaḿe E, et al.: Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6 and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol. 2005;95:236-240.
5. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, et al.: Suboptimal early inhibition of platelets by treatment with tirofiban and implication for coronary interventions. Am J Cardiol. 2002;89:647-650.
6. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, et al.: Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 2002;90:112-114.
7. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, et al.: The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. The ADVANCE Trial. J Am Coll Cardiol. 2004;44:14-19.
8. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, et al.: Tirofiban and sirolimus-eluting stent vs abciximab and bare metal stent for acute myocardial infarction: A randomized trial. JAMA. 2005;293:2109-2117.
9. Lakkis NM, George S, Thomas E, Ali M, Guyer K, et al.: Use of ICHOR-PlateletWorks to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Cathet Cardiovasc Intervent. 2001;53:346-351.
10. Moreno PR,Murcia AM, Palacios IF,LeonMN,Bernardi VH, et al.: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180-2184.
11. The BARI Investigators: Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769.
12. Weber C, Springer TA: Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alpha-IIb beta-3 and stimulated by platelet activating factor. J Clin Invest. 1997;100:2085-2093.
13. Nannizzi-Alaimo L, Alves VL, Phillips DR: Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123-1128.
14. The RESTORE investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96: 1445-1453.
15. Azar RR, Kassab R, Zoghbi A, Aboujaoud́e S, El-Osta H, et al.: Effects of clopidogrel on soluble CD40 ligand and on highsensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006;151:521.e1-521.e4.
16. Sarma J, LaanCA, AlamS, Jha A, Fox KAA, et al.: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105:2166-2171.
17. Kastrati A, Mehilli J, Schü hlen H, Dirschinger J, Dotzer F, et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-238.
18. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, et al.: Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 1999;33:97-106.
19. Gurbel PA, Bliden KP, Tantry US: Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha, and C-reactive protein release after elective stenting. Results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol. 2006;48: 2186-2191.